Table III.
Seroprevalence of HBoV DNA detected by nPCR in cancer patients and control groups.
| Cancer serum | Throat swab | Hepatitis serum | P-valuea | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Group | A HBoV |
B HBV |
C TTV |
D HBoV |
E HBoV |
A vs. B | A vs. C | A vs. D | A vs. E |
| Positive rate % (n)b | 36.7 (62/156) | 5.13 (8/156) | 6.41 (10/156) | 3.51 (33/941) | 7.08 (8/113) | 0.0001 | 0.0001 | 0.0001 | 0.0001 |
a
χ2 test.
b
Reported as the percentage (number) of patients, unless otherwise indicated.
nPCR, nested PCR; B19, parvovirus 19; HBoV, human bocavirus; HBV, hepatits B virus; TTV, transfusion transmitted virus.